Chemomab Therapeutics (CMMB) Long-Term Investments (2018)

Chemomab Therapeutics (CMMB) posted Long-Term Investments of $221000.0 for Q4 2018.

Chemomab Therapeutics (CMMB) Long-Term Investments (2018) Analysis & Trends

Chemomab Therapeutics' Long-Term Investments history runs 1 years deep, the most recent figure standing at $221000.0 for Q4 2018.

Quarterly Long-Term Investments changed N/A year-over-year to $221000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $221000.0 (changed N/A YoY) and the FY2018 annual result came in at $221000.0, changed N/A from the prior year.
Long-Term Investments was $221000.0 for Q4 2018 at Chemomab Therapeutics.
Across five years, Long-Term Investments topped out at $221000.0 in Q4 2018 and bottomed at $221000.0 in Q4 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Chemomab Therapeutics	124.14 Mn	113.77 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2018	221,000.00